The public production of medicines compared to the National Policy of Medicines and the burden of disease in Brazil

Abstract: The public production of medicines in Brazil by Government Pharmaceutical Laboratories has once again become the object of incentives, and Industrial Development Partnerships are one of the mechanisms adopted for the production of strategic medicines for the Brazilian Unified National Heal...

Full description

Saved in:
Bibliographic Details
Main Authors: Tatiana Aragão Figueiredo (Author), Joyce Mendes de Andrade Schramm (Author), Vera Lúcia Edais Pepe (Author)
Format: Book
Published: Escola Nacional de Saúde Pública, Fundação Oswaldo Cruz, 2017-09-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_2d8fe16e3b514e22b788cdef369f8a11
042 |a dc 
100 1 0 |a Tatiana Aragão Figueiredo  |e author 
700 1 0 |a Joyce Mendes de Andrade Schramm  |e author 
700 1 0 |a Vera Lúcia Edais Pepe  |e author 
245 0 0 |a The public production of medicines compared to the National Policy of Medicines and the burden of disease in Brazil 
260 |b Escola Nacional de Saúde Pública, Fundação Oswaldo Cruz,   |c 2017-09-01T00:00:00Z. 
500 |a 1678-4464 
500 |a 10.1590/0102-311x00179815 
520 |a Abstract: The public production of medicines in Brazil by Government Pharmaceutical Laboratories has once again become the object of incentives, and Industrial Development Partnerships are one of the mechanisms adopted for the production of strategic medicines for the Brazilian Unified National Health System (SUS). Considering that burden-of-disease studies have been used as a tool to define priority and essential medicines, the article compares the product portfolios of the country's Official Pharmaceutical Laboratories (OPL) and the list of strategic medicines for the SUS and burden of disease in Brazil in 2008. Of the 205 strategic medicines for the SUS and 111 from the portfolios, 73% and 89%, respectively, are on the National List of Essential Medicines (RENAME 2014). Some strategic medicines for the SUS are already produced by OPL and feature the selection of cancer drugs and biologicals. The current study contributes to the discussion on the public production of medicines in light of the country's current industrial policy and highlights the need to define priority drugs and the role of OPL in guaranteeing access to them. 
546 |a EN 
546 |a ES 
546 |a PT 
690 |a Burden of Disease 
690 |a Disabilty-adjusted Life Years 
690 |a Drug Industry 
690 |a Pharmaceutical Services 
690 |a Medicine 
690 |a R 
690 |a Public aspects of medicine 
690 |a RA1-1270 
655 7 |a article  |2 local 
786 0 |n Cadernos de Saúde Pública, Vol 33, Iss 9 (2017) 
787 0 |n http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S0102-311X2017001205001&lng=en&tlng=en 
787 0 |n https://doaj.org/toc/1678-4464 
856 4 1 |u https://doaj.org/article/2d8fe16e3b514e22b788cdef369f8a11  |z Connect to this object online.